New Weekly Injection Beats Dulaglutide for Blood Sugar & Weight

What Was Studied — and Why It Matters

Researchers wanted to know whether a new once-weekly injectable medication called mazdutide could control blood sugar better than an already-approved weekly injection, dulaglutide (brand name Trulicity), in adults with type 2 diabetes. This matters because millions of people with type 2 diabetes still struggle to hit their blood sugar targets — and many also need help managing their weight. A drug that tackles both problems at once could be a meaningful step forward.

How the Study Was Done

This was a rigorous, randomized phase III clinical trial — considered the gold standard in medical research. A total of 731 Chinese adults with type 2 diabetes were split into three groups. One group received 4 mg of mazdutide weekly, another received 6 mg of mazdutide weekly, and the third received 1.5 mg of dulaglutide weekly. All participants also continued taking their usual oral diabetes medications. The trial ran for 28 weeks (about seven months).

What the Researchers Found

The results were striking across two key areas:

• Blood sugar control: Both doses of mazdutide lowered HbA1c (a 3-month average blood sugar measure) more than dulaglutide. The 6 mg dose produced the biggest difference — about 0.30 percentage points better than dulaglutide. That may sound small, but in clinical practice it can meaningfully reduce the risk of long-term complications.
• Weight loss: This is where mazdutide really stood out. People taking 4 mg lost nearly 4% more of their body weight than those on dulaglutide; those on 6 mg lost almost 6% more. For someone weighing 200 lbs, that's up to 12 extra pounds of weight loss.
• Hitting both targets at once: Significantly more mazdutide users reached the combined goal of an HbA1c below 7% and at least 5% body weight loss — a dual achievement that's notoriously hard to reach.

What About Side Effects?

The most common side effects were nausea, vomiting, and diarrhea — the same stomach-related issues seen with most GLP-1 medications. These occurred more often with mazdutide than with dulaglutide, especially at the higher dose. For most participants, these effects were manageable, but it's important to talk with your doctor if stomach symptoms become disruptive.

What This Means for Real Patients

Mazdutide is not yet approved outside of clinical trials, but this study adds strong evidence that a new class of dual-action injections may offer better results than current options. If you're already using a GLP-1 medication like dulaglutide — and managing your supplies through a trusted provider like MDS Diabetes — this research is a reason to stay engaged with your care team about emerging options. Proper storage and consistent weekly dosing of injectable medications remain essential, and MDS Diabetes can help ensure you always have what you need on hand.

Bottom Line

In a well-designed 28-week trial, mazdutide outperformed dulaglutide on both blood sugar control and weight loss in adults with type 2 diabetes. Side effects were mostly digestive and more common with mazdutide. While this medication isn't widely available yet, it represents a promising new direction in diabetes treatment — one worth watching closely.